Overview
The oxytocin studies linked here cover different populations, delivery methods and outcomes. The trial excerpt below reports both an overall null result and a subgroup observation; the full study records preserve that context.[1] Keep the population, route and measured outcome attached to each result. Studies of oxytocin analogues remain filed under their own research topic.[1] The sections below distinguish measured findings from broader benefit claims and identify the information needed to interpret formulation, timing, and safety. A result remains attached to the population and intervention in which it was observed.
Benefits
This guide links 26 study records for Oxytocin, but the presence of records is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.
Safety
This Oxytocin guide does not yet provide a complete clinical safety assessment for a specific formulation and use. Such an assessment would need the exposure, route, participant characteristics, adverse events, and duration of follow-up from the relevant primary studies. Missing safety information cannot be interpreted as an absence of risk, and a reported event needs context before causation is assigned. Findings from one setting should remain separate from claims about another product, population, or combination.
Contraindications
The evidence summarized on this Oxytocin page is not sufficient to construct a complete contraindication list for clinical use. A study’s inclusion and exclusion criteria describe its selected participants, but they do not determine suitability for everyone outside that study. Interpreting a potential contraindication requires the exact product, intended use, health condition, and supporting evidence. This section therefore leaves unanswered suitability questions explicit instead of turning unstudied circumstances into either permission or a categorical clinical rule.
Interactions
This guide does not establish an interaction profile for Oxytocin with other peptides, medicines, or supplements. To evaluate a particular combination, the relevant evidence would need to identify the coadministered substances, formulation, route, and measured effects. Results for ingredients studied separately cannot determine whether combining them changes benefit, exposure, or harm. Related stack pages distinguish those ingredient findings from direct combination evidence and keep any unresolved interaction questions visible.
Forms & dosing
A validated dosing recommendation for Oxytocin cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.
Results & stopping
This Oxytocin guide does not establish a general time to benefit or what happens after treatment stops. Those questions require a defined outcome, repeated measurements, and follow-up that extends beyond the intervention when persistence is being assessed. A pharmacological response during exposure would answer a different question from a sustained improvement in symptoms or function. Any future timeline should therefore state exactly what changed, when it was measured, and whether the study actually observed participants after discontinuation.
Product quality
The studies attached to a topic do not, by themselves, validate the quality of a commercial Oxytocin product. Evaluating a particular preparation requires information about its identity, composition, batch, and intended route, with testing appropriate to the claim being made. A supplier’s label cannot establish that the contents match a research intervention. This guide keeps product characterization separate from clinical effectiveness and does not endorse a vendor or finished product on the basis of an ingredient study.
Status
This page does not provide a verified, product-specific regulatory determination for Oxytocin. Approval, research use, and availability need to be distinguished for the exact preparation, indication, and jurisdiction being considered. A publication establishes that an experiment was reported; it does not by itself establish authorization to market a product. Regulatory conclusions should be added only with a dated primary agency source, while research findings remain tied to the intervention actually investigated.
Evidence
These assessments describe confidence in a specific outcome for the population and formulation actually studied. Select an outcome or source count to inspect the supporting sources, methods, and limitations before applying a finding to a broader claim. Research on an individual ingredient is kept separate from evidence about a complete stack, and laboratory findings are distinguished from clinical outcomes. An unassessed question remains unresolved; it should not be read as evidence of either effectiveness or ineffectiveness. How we grade evidence.
| Outcome, finding and study design | Evidence certainty | Sources |
|---|---|---|
No outcome assessment is available for this guide yet. Source records below have not been synthesized into an assessment of benefit or safety. Inspect the available research | ||
Research Feed
Studies
Open a study to read its findings and limits, then explore the source passages and PDF details. Numbered citations link to References below.
A phase 1 evaluation of inhaled oxytocin: Physiologicallybased pharmacokinetic model informed dosing of a novel heat-stable oxytocin delivery system
Behavioral effects of multiple-dose oxytocin treatment in autism: a randomized, placebo-controlled trial with long-term follow-up
Dose-dependent social-cognitive effects of intranasal oxytocin delivered with novel Breath Powered device in adults with autism spectrum disorder: a randomized placebo-controlled double-blind crossover trial
Effects of multiple‑dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo‑controlled trial
Effects of Oxytocin and Prosocial Behavior on Brain Responses to Direct and Vicariously Experienced Pain
Effects of route of administration on oxytocininduced changes in regional cerebral blood flow in humans
Elevated cerebrospinal fluid and blood concentrations of oxytocin following its intranasal administration in humans
Gut microbiota varies by opioid use, circulating leptin and oxytocin in African American men with diabetes and high burden of chronic disease
Intranasal Oxytocin Enhances Connectivity in the Neural Circuitry Supporting Social Motivation and Social Perception in Children with Autism
Intranasal oxytocin enhances intrinsic corticostriatal functional connectivity in women
Intranasal oxytocin increases neural responses to social reward in post-traumatic stress disorder
Intranasal oxytocin reduces provoked symptoms in female patients with posttraumatic stress disorder despite exerting sympathomimetic and positive chronotropic effects in a randomized controlled trial
Low-dose oxytocin delivered intranasally with Breath Powered device affects social-cognitive behavior: a randomized fourway crossover trial with nasal cavity dimension assessment
No Evidence that MDMA-Induced Enhancement of Emotional Empathy Is Related to Peripheral Oxytocin Levels or 5-HT1a Receptor Activation
Oxytocin efficacy is modulated by dosage and oxytocin receptor genotype in young adults with high-functioning autism: a 24-week randomized clinical trial
Oxytocin increases eye contact during a real-time, naturalistic social interaction in males with and without autism
Oxytocin Increases Heart Rate Variability in Humans at Rest: Implications for Social Approach-Related Motivation and Capacity for Social Engagement
Oxytocin may be useful to increase trust in others and decrease disruptive behaviours in patients with Prader-Willi syndrome: a randomised placebo-controlled trial in 24 patients
Probiotic and Oxytocin Combination Therapy in Patients with Autism Spectrum Disorder: A Randomized, Double-Blinded, Placebo-Controlled Pilot Trial
Restoring effects of oxytocin on the attentional preference for faces in autism
Salivary Oxytocin Concentrations in Males following Intranasal Administration of Oxytocin: A Double-Blind, Cross-Over Study
The Impact of Oxytocin on Food Intake and Emotion Recognition in Patients with Eating Disorders: A Double Blind Single Dose Within- Subject Cross-Over Design
The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial
The effect of oxytocin nasal spray on social interaction in young children with autism: a randomized clinical trial
Selected passages
A total of 87 children (aged between 3 and 12 years) with autism received 16 International Units (IU) of oxytocin (n = 45) or placebo (n = 42) nasal spray, morning and night (32 IU per day) for twelve weeks, following a 3-week placebo lead-in phase.
The_effect_of_oxytocin_nasal_spray_on_social_interaction_in_young_childr_36302965_PMC9607840.pdf · PDF page 1
The first primary outcome measure was the caregivercompleted Social Responsiveness Scale, Second Edition (SRS-2) [24].
The_effect_of_oxytocin_nasal_spray_on_social_interaction_in_young_childr_36302965_PMC9607840.pdf · PDF page 2
Overall, there was no effect of oxytocin treatment over time on the caregiver-rated Social Responsiveness Scale (SRS-2) (p = 0.686). However, a significant interaction with age (p = 0.028) showed that for younger children, aged 3–5 years, there was some indication of a treatment effect. Younger children who received oxytocin showed improvement on caregiver-rated social responsiveness ( SRS-2). There was no other evidence of benefit in the sample as a whole, or in the younger age group, on the clinician-rated Clinical Global Improvement Scale (CGI-S), or any secondary measure.
The_effect_of_oxytocin_nasal_spray_on_social_interaction_in_young_childr_36302965_PMC9607840.pdf · PDF page 1
The effect of oxytocin on attention to angry and happy faces in chronic depression
Treatment of Obesity and Diabetes Using Oxytocin or Analogs in Patients and Mouse Models
FAQs
What can this guide currently establish about Oxytocin?
This guide links 26 study records for Oxytocin, but the presence of records is not itself an assessment of clinical benefit. A useful benefit claim needs an identifiable outcome, an appropriate comparison, and a description of who or what was studied. Laboratory activity, a biomarker response, and an improvement in symptoms should be assessed separately. Until the relevant results and limitations have been evaluated, this guide does not assign an effectiveness grade or translate a proposed use into an established benefit.
Do reported study amounts establish a dosing recommendation?
A validated dosing recommendation for Oxytocin cannot be inferred from the material currently summarized in this guide. When study records report an amount or concentration, that value belongs to the specific preparation, route, schedule, and experimental setting described in the source. Laboratory concentrations and human treatment regimens should remain separately identified. This page will not convert an isolated reported number into a consumer dose, a cycle, or a protocol for a different formulation or combination.
Update History
Evidence and review status
- Recorded source check
- Subsequent substantive evidence update
- No later update is recorded for Oxytocin.
- Independent clinical review
- Pending; this selected-source guide is AI-assisted.
A source-check date is not an exhaustive literature-search cutoff or an independent approval. Adding a paper to the catalogue does not mean its findings have been incorporated into an outcome assessment.
Read the editorial methodReferences
1 sources
- The_effect_of_oxytocin_nasal_spray_on_social_interaction_in_young_childr_36302965_PMC9607840.pdf (Accessed 2026-10-04)Primary research · See study record for population and routeReview status · PendingSave study
